Victrex (LON:VCT - Get Free Report) had its price target dropped by equities researchers at JPMorgan Chase & Co. from GBX 940 ($12.77) to GBX 818 ($11.11) in a research note issued on Wednesday, MarketBeat Ratings reports. The firm presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 12.92% from the company's current price.
Victrex Trading Down 0.5%
Shares of Victrex stock traded down GBX 3.60 ($0.05) on Wednesday, reaching GBX 724.40 ($9.84). 171,582 shares of the company were exchanged, compared to its average volume of 414,972. The stock has a fifty day moving average price of GBX 795.78 and a 200-day moving average price of GBX 890.75. The firm has a market capitalization of £631.91 million, a price-to-earnings ratio of 20.58, a price-to-earnings-growth ratio of 1.92 and a beta of 0.69. The company has a current ratio of 4.39, a quick ratio of 1.99 and a debt-to-equity ratio of 10.93. Victrex has a fifty-two week low of GBX 667.62 ($9.07) and a fifty-two week high of GBX 1,160 ($15.76).
Victrex (LON:VCT - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported GBX 22.60 ($0.31) EPS for the quarter. Victrex had a net margin of 10.81% and a return on equity of 6.67%. On average, analysts expect that Victrex will post 73.1078905 EPS for the current year.
Insiders Place Their Bets
In other Victrex news, insider David Thomas purchased 1,158 shares of the business's stock in a transaction on Tuesday, May 13th. The stock was purchased at an average price of GBX 846 ($11.49) per share, for a total transaction of £9,796.68 ($13,308.90). Also, insider Dame Vivienne Cox purchased 2,747 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were acquired at an average price of GBX 721 ($9.79) per share, with a total value of £19,805.87 ($26,906.49). 1.64% of the stock is owned by insiders.
Victrex Company Profile
(
Get Free Report)
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.
Further Reading
Before you consider Victrex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list.
While Victrex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
